Ole Isacson

List of Publications by Citations

33 papers	2,284 citations	21 h-index	47 g-index
53 ext. papers	2,630 ext. citations	11.9 avg, IF	4.81 L-index

#	Paper	IF	Citations
33	Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. *Nature Medicine*, **1997**, 3, 350-3	50.5	406
32	Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. *Magnetic Resonance in Medicine*, **1997**, 38, 389-98	4.4	216
31	Transplanted xenogeneic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres. *Nature Medicine*, **1995**, 1, 1189-94	50.5	209
30	Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh. *Trends in Neurosciences*, **2002**, 25, 79-84	13.3	153
29	Progressive decline of glucocerebrosidase in aging and Parkinson's disease. *Annals of Clinical and Translational Neurology*, **2015**, 2, 433-8	5.3	122
28	A high-efficiency synthetic promoter that drives transgene expression selectively in noradrenergic neurons. *Human Gene Therapy*, **2001**, 12, 1731-40	4.8	122
27	The Threshold Theory for Parkinson's Disease. *Trends in Neurosciences*, **2017**, 40, 4-14	13.3	111
26	Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons. *Neurobiology of Disease*, **2015**, 82, 495-503	7.5	88
25	The production and use of cells as therapeutic agents in neurodegenerative diseases. *Lancet Neurology, The*, **2003**, 2, 417-24	24.1	88
24	Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice. *Antioxidants and Redox Signaling*, **2015**, 23, 550-64	8.4	79
23	Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease. *Molecular Neurodegeneration*, **2019**, 14, 40	19	56
22	Glycosphingolipid levels and glucocerebrosidase activity are altered in normal aging of the mouse brain. *Neurobiology of Aging*, **2018**, 67, 189-200	5.6	50
21	Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism. *Neurobiology of Disease*, **2008**, 30, 430-438	7.5	50
20	Enhanced ubiquitin-dependent degradation by Nedd4 protects against α-synuclein accumulation and toxicity in animal models of Parkinson's disease. *Neurobiology of Disease*, **2014**, 64, 79-87	7.5	46
19	The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson's disease patients and increases after lysosomal stress. *Neurobiology of Disease*, **2018**, 120, 1-11	7.5	39
18	Behavioral effects and gene delivery in a rat model of Parkinson's disease. *Science*, **1995**, 269, 856-7	33.3	36
17	Article Commentary: Development of the Human Striatum: Implications for Fetal Striatal Transplantation in the Treatment of Huntington's Disease. *Cell Transplantation*, **1995**, 4, 539-545	4	33

List of Publications

16	A primate model of Huntington's disease: functional neural transplantation and CT-guided stereotactic procedures. *Cell Transplantation*, **1992**, 1, 313-22	4	30
15	Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice. *Molecular Therapy - Nucleic Acids*, **2020**, 21, 623-635	10.7	18
14	Cell type-specific lipid storage changes in Parkinson's disease patient brains are recapitulated by experimental glycolipid disturbance. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 27646-27654	11.5	17
13	Genetic Variants of Microtubule Actin Cross-linking Factor 1 (MACF1) Confer Risk for Parkinson's Disease. *Molecular Neurobiology*, **2017**, 54, 2878-2888	6.2	16
12	Neuronal xenotransplantation in Parkinson's disease. *Nature Medicine*, **1997**, 3, 474-5	50.5	11
11	ALS-associated peripherin spliced transcripts form distinct protein inclusions that are neuroprotective against oxidative stress. *Experimental Neurology*, **2014**, 261, 217-29	5.7	9
10	hVMAT2: A Target of Individualized Medication for Parkinson's Disease. *Neurotherapeutics*, **2016**, 13, 623-34	6.4	8
9	Parkinsonian monkeys with prior levodopa-induced dyskinesias followed by fetal dopamine precursor grafts do not display graft-induced dyskinesias. *Journal of Comparative Neurology*, **2017**, 525, 498-512	3.4	6
8	Lysosomes to combat Parkinson's disease. *Nature Neuroscience*, **2015**, 18, 792-3	25.5	6
7	Upregulating β-hexosaminidase activity in rodents prevents β-synuclein lipid associations and protects dopaminergic neurons from β-synuclein-mediated neurotoxicity. *Acta Neuropathologica Communications*, **2020**, 8, 127	7.3	6
6	Fibroblasts from idiopathic Parkinson's disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2. *Molecular Brain*, **2021**, 14, 16	4.5	5
5	The Consequences of Coronavirus-Induced Cytokine Storm Are Associated With Neurological Diseases, Which May Be Preventable. *Frontiers in Neurology*, **2020**, 11, 745	4.1	4
4	Comprehensive Cell Surface Antigen Analysis Identifies Transferrin Receptor Protein-1 (CD71) as a Negative Selection Marker for Human Neuronal Cells. *Stem Cells*, **2019**, 37, 1293-1306	5.8	2
3	Part B: Directed Differentiation of Human Embryonic Stem Cells into Dopaminergic Neurons337-347		2
2	Glycosphingolipid metabolism and its role in ageing and Parkinson's disease. *Glycoconjugate Journal*, **2021**, 1	3	2
1	Ole Isacson: development of new therapies for Parkinson's disease (interview). *Journal of Visualized Experiments*, **2007**, 189	1.6	1